PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs GNPX's -10.55%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Cash + STI yoy 0.5-0.75x GNPX's -10.55%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
0.75-0.9x GNPX's -8.78%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-20.34%
1.25-1.5x GNPX's -13.85%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
≥ 1.5x GNPX's -0.42%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
0.75-0.9x GNPX's -8.06%. Bill Ackman questions if competitor invests more aggressively for growth.
-4.95%
Less than half of GNPX's 28.75%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
-89.58%
Less than half of GNPX's 84.91%. David Dodd sees fewer expansions in other current obligations.
-16.33%
Less than half of GNPX's 50.43%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Less than half of GNPX's 28.75%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Less than half of GNPX's 50.43%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
Below half GNPX's -7.33%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to GNPX's zero value, indicating worse performance.
-6.40%
0.5-0.75x GNPX's -10.30%. Martin Whitman is wary of lagging equity growth vs. competitor.
-7.25%
0.75-0.9x GNPX's -8.06%. Bill Ackman wonders if competitor invests or leverages more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
7.35%
50-75% of GNPX's 10.55%. Bruce Berkowitz notes comparatively lower net debt expansion.